期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

原发性中晚期乳腺癌新辅助化疗的临床研究 被引量：1

下载PDF
导出
摘要 目的:探讨原发性中晚期乳腺癌新辅助化疗的方法及临床价值。方法:回顾性分析应用新辅助化疗治疗原发性中晚期乳腺癌患者200例的临床资料。结果:经新辅助化疗后,总有效率达74.5%(149/200)。无病变进展病例。结论:原发性中晚期乳腺癌新辅助化疗效果较为明显,对于患者生活质量的提高很有帮助。
作者 李亮 张锦宏 黄国杰
机构地区 广东省梅州市人民医院肿瘤内科
出处 《吉林医学》 CAS 2011年第3期477-478,共2页 Jilin Medical Journal
关键词 原发性中晚期乳腺癌 新辅助化疗 恶性肿瘤
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献3

  • 1EC,Smith M L,Somlo G,et al.NCCN Breast Cancer ClinicalPractice Guiddiues Panel[J].Natl Compr Cane Netw,2009,7(2):122.
  • 2张保宁,邵志敏,乔新民,李波,姜军,杨名添,王水,宋三泰,张斌,杨红健.中国乳腺癌保乳治疗的前瞻性多中心研究[J].中华肿瘤杂志,2005,27(11):680-684. 被引量：247
  • 3Kaufmann P,Dauphine C E,Vargas M P,et al.Success ofpre-operative chemotherapy in conversion ofmastectomy to bmastconservation surgery[J].Am Surg,2006,72(3):935.

二级参考文献20

  • 1Bedwinek J. Treatment of stage I and Ⅱ adenocarcinoma of the breast by tumor excision and irradiation. Int J Radiat Oncol Biol Phys, 1981,7: 1553-1559.
  • 2Park CC, Mitsumori M, Nixon A, et al. Outcome at 8 years after breast-conserving surgery and radiation therapy for invasive breast cancer: influence of margin status and systemic therapy on local recurrence. J Clin Oncol,2000, 18: 1668-1675.
  • 3Smitt MC, Nowels KW, Zdeblick MJ, et al. The importance of the lumpectomy surgical margin status in long-term results of breast conservation. Cancer, 1995,76:259-267.
  • 4Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med,2001,345:1378-1387.
  • 5National Institutes of Health. NIH consensus conference on the treatment of early-stage breast cancer. JAMA,1991,265:391-395.
  • 6Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med,2002,347: 1233-1241.
  • 7Liljegren G, Holmberg L, Bergh J, et al. 10-Year results after sector resection with or without postoperative radiotherapy for stage I breast cancer: a randomized trial. J Clin Oncol,1999,17:2326-2333.
  • 8Renton SC, Gazet JC, Ford HT, et al. The importance of resection margin in conservative surgery for breast cancer. Eur J Surg Oncol,1996,22:17-22.
  • 9Clark RM, Whelan T, Levine M, et al. Randomized clinical trial of breast irradiation following lumpectomy and axillary dissection for node-negative breast cancer: an update. Ontario Clinical Oncology Group. J Natl Cancer Inst,1996,88:1659-1664.
  • 10Forrest AP, Stewart HJ, Everington D, et al. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group. Lancet,1996,348:708-713.

共引文献246

同被引文献13

  • 1Fang M, Toher J, Morgan M,et al. Genomic differences betweenestrogen receptor(ER)-positive and ER-negative human breastcarcinoma identified by single nucleotide polymorphism arraycomparative genome hybridization analysis. Cancer. 2011, 117(10):2024-2034.
  • 2Gruver AM, Portier BP, Tubbs RR. Molecular pathology of breastcancer: the journey from traditional practice toward embracing thecomplexity of a molecular classification. Arch Pathol Lab Med,2011, 135 (5):544-557.
  • 3Veronesi U, Cascinelli N, Marlani L, et al. Twenty year follow upof a randomized study comparing breast conserving surgerywithradicalmastectrany for eaily breast cancer. N Engle J Med, 2002,347(16):1227-1232.
  • 4Fisher B,Anderson S,Bryant J, et al. Twenty year follow-up of arandomized trial comparing total mastectomy, lumpectomy, andlumpectomy plusirradiation for the treatment of invasive breastcancer. N Engle J Med, 2002, 347(16):1233-1241.
  • 5Winchester DP, Jeske JM, Golds chmidt RA. The diagnosis andmanagement of ductal carcinoma insitu of the breast. CA Cancer JClin, 2000, 50(3):184-200.
  • 6Gordils Perez J, Raslins Duell R, Kelvin JF. Advances in radiationtreatment of patients with breast cancer. Clin J Oncol Nurs, 2003,7(6): 629-636.
  • 7Huang EH, Tucker SL, Strom EA, et al. Postmastectomy radiationimproves local regional control and survival for selected patientswith locally advanced breast cancer treated with neoadjuvantchemotherapy and mastectomy. J Clin Oncol, 2004, 22(23): 4691-4699.
  • 8Romond EH, Perez E, Bryant J, et al. Trastuzumab plus adjuvantchemotherapy for operable HER-2 positive breast cancer. N Engl JMed, 2005,353(16):1673-1684.
  • 9李华斌,李晓娟,朱晓谦,张连平.乳腺癌诊治发展的趋势[J].中国普通外科杂志,2007,16(11):1099-1101. 被引量：9
  • 10李菊梅,韩建军,郭梅艳.VEGF和TNF-α在乳腺癌中的表达及临床意义[J].河北医药,2009,31(18):2377-2378. 被引量：8

引证文献1

二级引证文献2

吉林医学
2011年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部